Literature DB >> 11985528

Predictors of HIV-specific lymphocyte proliferative immune responses induced by therapeutic vaccination.

R B Moss1, M R Wallace, R T Steigbigel, S A Morrison, W K Giermakowska, C J Nardo, J P Diveley, D J Carlo.   

Abstract

We treated a cohort of 38 HIV-infected individuals with a therapeutic vaccine (REMUNE, HIV-1 Immunogen) in an open label study. We then determined whether baseline parameters, such as CD4 cell count, viral load and IgG levels, were predictive of the magnitude of the HIV-specific lymphocyte proliferative responses (LPRs). We demonstrate herein that there is a significant enhancement from baseline for both HIV and p24 antigen-stimulated LPRs after immunization. Using a responder definition of a stimulation index of >5 on at least two post-immunization time-points, 29/38 (76%) responded to HIV-1 antigen while 27/38 (71%) responded to native p24 antigen. Viral load and total IgG were negatively correlated, while CD4 cell counts were positively associated with the magnitude of the HIV antigen LPR. In a multivariable analysis, baseline CD4 was the best predictor of HIV antigen LPR post-immunization.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11985528      PMCID: PMC1906388          DOI: 10.1046/j.1365-2249.2002.01835.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

1.  The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs.

Authors:  J L Turner; J R Kostman; A Aquino; D Wright; S Szabo; R Bidwell; J Goodgame; A Daigle; E Kelley; F Jensen; C Duffy; D Carlo; R B Moss
Journal:  HIV Med       Date:  2001-04       Impact factor: 3.180

2.  Immune control of HIV-1 after early treatment of acute infection.

Authors:  E S Rosenberg; M Altfeld; S H Poon; M N Phillips; B M Wilkes; R L Eldridge; G K Robbins; R T D'Aquila; P J Goulder; B D Walker
Journal:  Nature       Date:  2000-09-28       Impact factor: 49.962

3.  Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214.

Authors:  R T Schooley; C Spino; D Kuritzkes; B D Walker; F A Valentine; M S Hirsch; E Cooney; G Friedland; S Kundu; T C Merigan; M J McElrath; A Collier; S Plaeger; R Mitsuyasu; J Kahn; P Haslett; P Uherova; V deGruttola; S Chiu; B Zhang; G Jones; D Bell; N Ketter; T Twadell; D Chernoff; M Rosandich
Journal:  J Infect Dis       Date:  2000-10-09       Impact factor: 5.226

4.  HIV type 1 isolate Z321, the strain used to make a therapeutic HIV type 1 immunogen, is intersubtype recombinant.

Authors:  D J Choi; S Dube; T P Spicer; H B Slade; F C Jensen; B J Poiesz
Journal:  AIDS Res Hum Retroviruses       Date:  1997-03-01       Impact factor: 2.205

5.  Human immunodeficiency virus isolated from a serum sample collected in 1976 in Central Africa.

Authors:  J P Getchell; D R Hicks; A Svinivasan; J L Heath; D A York; M Malonga; D N Forthal; J M Mann; J B McCormick
Journal:  J Infect Dis       Date:  1987-11       Impact factor: 5.226

6.  Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial.

Authors:  J O Kahn; D W Cherng; K Mayer; H Murray; S Lagakos
Journal:  JAMA       Date:  2000-11-01       Impact factor: 56.272

7.  T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART).

Authors:  M D Hazenberg; J W Stuart; S A Otto; J C Borleffs; C A Boucher; R J de Boer; F Miedema; D Hamann
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

8.  Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection.

Authors:  J J Eron; M A Ashby; M F Giordano; M Chernow; W M Reiter; S G Deeks; J P Lavelle; M A Conant; B G Yangco; P G Pate; R A Torres; R T Mitsuyasu; T Twaddell
Journal:  Lancet       Date:  1996-12-07       Impact factor: 79.321

9.  Effect of gamma irradiation on the human immunodeficiency virus and human coagulation proteins.

Authors:  A D Kitchen; G F Mann; J F Harrison; A J Zuckerman
Journal:  Vox Sang       Date:  1989       Impact factor: 2.144

10.  Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells.

Authors:  R J Trauger; F Ferre; A E Daigle; F C Jensen; R B Moss; S H Mueller; S P Richieri; H B Slade; D J Carlo
Journal:  J Infect Dis       Date:  1994-06       Impact factor: 5.226

View more
  2 in total

1.  Antigen-presenting cell modulation induces a memory response to p24 in peripheral blood leukocytes from human immunodeficiency virus-infected individuals.

Authors:  Michael A Kolber; Maria O Saenz
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

2.  Immune reconstitution and viral stimulation are required to restore HIV-specific CD8 T cell responses following advanced infection.

Authors:  Jane Gamberg; Lisa Barrett; Ian Bowmer; Constance Howley; Michael Grant
Journal:  J Clin Immunol       Date:  2004-03       Impact factor: 8.542

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.